N
Nobuo Kato
Researcher at Osaka University
Publications - 202
Citations - 3834
Nobuo Kato is an academic researcher from Osaka University. The author has contributed to research in topics: Tropone & Total synthesis. The author has an hindex of 27, co-authored 202 publications receiving 3448 citations. Previous affiliations of Nobuo Kato include Kyushu University.
Papers
More filters
Journal ArticleDOI
Semi-wet peptide/protein array using supramolecular hydrogel
TL;DR: A novel semi-wet peptide/protein microarray using a supramolecular hydrogel composed of glycosylated amino acetate that overcomes several drawbacks of conventional protein chips, and thus can have potential applications in pharmaceutical research and diagnosis.
Journal ArticleDOI
Photochromism of 1,2-Bis(2-methyl-5-phenyl-3-thienyl)perfluorocyclopentene in a Single-Crystalline Phase
TL;DR: In this paper, the photocycloreversion reactions in the single-crystalline phase were observed in a closed-ring isomer of 1,2-Bis(2-methyl-5-phenyl-3-thienyl)perfluorocyclopentene.
Journal ArticleDOI
Fusicoccins are biosynthesized by an unusual chimera diterpene synthase in fungi
Tomonobu Toyomasu,Mai Tsukahara,Akane Kaneko,Rie Niida,Wataru Mitsuhashi,Tohru Dairi,Nobuo Kato,Takeshi Sassa +7 more
TL;DR: It is found that (+)-fusicocca-2,10 (14)-diene, a tricyclic hydrocarbon precursor for fusicoccins, is biosynthesized from the C5 isoprene units by an unusual multifunctional enzyme, P. amygdali fusICoccadiene synthase (PaFS), which shows both prenyltransferase and terpene cyclase activities.
Journal ArticleDOI
On the scope, mechanism and stereochemistry of the Lewis acid catalyzed cyclocondensation of activated dienes with aldehydes: an application to the erythronolide problem
Journal ArticleDOI
Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant Cancers.
Manuela Molzan,Stefan Kasper,Lars Röglin,Malgorzata Skwarczynska,Takeshi Sassa,Takatsugu Inoue,Frank Breitenbuecher,Junko Ohkanda,Junko Ohkanda,Nobuo Kato,Martin Schuler,Christian Ottmann +11 more
TL;DR: Combined treatment with cotylenin-A and an anti-EGFR antibody synergistically suppresses tumor growth in vitro and in vivo and defines a novel pharmacologic strategy for treatment of RAS mutant cancers.